In vitro and in vivo preclinical profile of abediterol (LAS100977), an inhaled long-acting β2-adrenoceptor agonist, compared with indacaterol, olodaterol and vilanterol.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  European Journal of Pharmacology

• Publication date

  2016-01-05

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejphar.2015.11.053PMID 26656755
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution

  2023cited by this paper
• Abediterol (LAS100977), a novel long-acting β2-agonist: efficacy, safety and tolerability in persistent asthma.

  2014cited by this paper
• Abediterol, a novel long-acting inhaled β2-agonist, has a fast association rate and long residence time at human β2 receptors

  2014cited by this paper
• COPD: adherence to therapy

  2014cited by this paper
• First‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long‐acting Β2‐agonist

  2014cited by this paper
• A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma; a Phase II, randomized study

  2014cited by this paper
• Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study

  2013cited by this paper
• In Vitro Pharmacological Characterization of Vilanterol, a Novel Long-Acting β2-Adrenoceptor Agonist with 24-Hour Duration of Action

  2013cited by this paper
• β2-agonist therapy in lung disease.

  2013cited by this paper
• Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD.

  2013cited by this paper
• Lung function efficacy of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Two 48-week studies

  2013cited by this paper
• Slow receptor dissociation is not a key factor in the duration of action of inhaled long‐acting β2‐adrenoceptor agonists

  2012cited by this paper
• Pharmacological Characterization of Abediterol, a Novel Inhaled β2-Adrenoceptor Agonist with Long Duration of Action and a Favorable Safety Profile in Preclinical Models

  2012cited by this paper
• Comparative effectiveness of drugs for chronic obstructive pulmonary disease.

  2012cited by this paper
• Optimum Bronchodilator Combinations in Chronic Obstructive Pulmonary Disease

  2012cited by this paper
• Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs.

  2011cited by this paper
• Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPD.

  2011cited by this paper
• 24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD.

  2011cited by this paper
• Functional and Biochemical Rationales for the 24-Hour-Long Duration of Action of Olodaterol

  2011cited by this paper
• Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium

  2010cited by this paper
• The short, the long and the “ultra-long”: Why duration of bronchodilator action matters in chronic obstructive pulmonary disease

  2010cited by this paper
• Pharmacological Characterization of Olodaterol, a Novel Inhaled β2-Adrenoceptor Agonist Exerting a 24-Hour-Long Duration of Action in Preclinical Models

  2010cited by this paper
• 24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterol.

  2010cited by this paper
• Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties?

  2009cited by this paper
• Pharmacological Characterization of Indacaterol, a Novel Once Daily Inhaled β2 Adrenoceptor Agonist, on Small Airways in Human and Rat Precision-Cut Lung Slices

  2008cited by this paper
• Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD: A 28-day randomised, placebo controlled clinical trial

  2007cited by this paper
• Effect of indacaterol, a novel long-acting β2-agonist, on isolated human bronchi

  2007cited by this paper
• Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.

  2007cited by this paper
• Beyond the dogma: novel beta2-adrenoceptor signalling in the airways.

  2006cited by this paper
• Beyond the dogma: novel β2-adrenoceptor signalling in the airways

  2006cited by this paper
• In Vitro and in Vivo Pharmacological Characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (Indacaterol), a Novel Inhaled β2 Adrenoceptor Agonist with a 24-h Duration of Action

  2006cited by this paper
• Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs.

  2005cited by this paper
• β2-Adrenergic receptors: Structure, regulation and signaling by partial and full agonists

  2004cited by this paper
• Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis.

  2004cited by this paper
• Adverse effects of beta-agonists.

  2002cited by this paper
• Adverse effects of -agonists

  2002cited by this paper
• Patterns of cardiovascular pathology induced by diverse cardioactive drugs.

  2000cited by this paper
• Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects

  2000cited by this paper
• Novel and versatile superfusion system. Its use in the evaluation of some spasmogenic and spasmolytic agents using guinea-pig isolated tracheal smooth muscle.

  1989cited by this paper
• Role of beta 1-receptors and vagal tone in cardiac inotropic and chronotropic responses to a beta 2-agonist in humans.

  1989cited by this paper

• An Open-Label, Single-Arm, Multicenter, Prospective, Post-Marketing Study to Evaluate the Effectiveness and Safety of Fluticasone Furoate/Vilanterol (FF/VI) Dry Powder Inhaler (DPI) in the Management of Asthma Patients (PROMISE-OD)

  2026cites this paper
• Asthma and COPD: A Focus on β-Agonists - Past, Present and Future.

  2023cites this paper
• Optimization of Long-Acting Bronchodilator Dose Ratios Using Isolated Guinea Pig Tracheal Rings for Synergistic Combination Therapy in Asthma and COPD

  2022cites this paper
• Tumor Necrosis Factor-α Mediates Lung Injury in the Early Phase of Endotoxemia

  2022cites this paper
• A Look at the Importance of Chirality in Drug Activity: Some Significative Examples

  2022cites this paper
• State-of-the-art beta-adrenoreceptor agonists for the treatment of asthma

  2021cites this paper
• Chirality of β2-agonists. An overview of pharmacological activity, stereoselective analysis, and synthesis

  2020cites this paper
• Recent Advances in β2-Agonists for Treatment of Chronic Respiratory Diseases and Heart Failure.

  2020cites this paper
• Ultra-LABAs for the treatment of asthma.

  2019cites this paper
• Pharmacological Profile of AZD8871 (LAS191351), a Novel Inhaled Dual M3 Receptor Antagonist/β2-Adrenoceptor Agonist Molecule with Long-Lasting Effects and Favorable Safety Profile

  2019influential citation
• Pulmonary , gastrointestinal and urogenital pharmacology Abediterol ( LAS 100977 ) , an inhaled long-acting β 2-adrenoceptor agonist , has a fast association rate and long residence time at receptor ☆

  2018cites this paper
• Synthesis and biological evaluation of β2-adrenoceptor agonists bearing the 2-amino-2-phenylethanol scaffold.

  2018cites this paper
• Synthesis, biological evaluation and molecular modeling of 2-amino-2-phenylethanol derivatives as novel β2-adrenoceptor agonists.

  2018cites this paper
• Bronchoprotective effect of vilanterol against methacholine-induced bronchoconstriction in mild asthmatics: A randomized three-way crossover study.

  2018cites this paper
• -AGONISTS IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

  2017cites this paper
• Next generation beta adrenoreceptor agonists for the treatment of asthma

  2017influential citation
• Intracellular interactions of umeclidinium and vilanterol in human airway smooth muscle

  2017influential citation
• Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease

  2017cites this paper
• Pharmacological preclinical characterization of LAS190792, a novel inhaled bifunctional muscarinic receptor antagonist /β2-adrenoceptor agonist (MABA) molecule.

  2017cites this paper
• Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD

  2017cites this paper
• New bronchodilators in treatment of chronic obstructive pulmonary disease

  2016cites this paper
• Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy

  2016influential citation